Chordia Therapeutics Inc. (190A) AI Stock Analysis

• Market Cap: ¥9.11B
• Dividend Yield: N/A
• Average Volume (3M): 565.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -4.24
• Shares Outstanding: 71,167,900
• 10 Day Avg. Volume: 542,310
• 30 Day Avg. Volume: 565,443
• PEG Ratio: 0.42
• Price to Book (P/B): 5.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ¥128.00 ▲(18.52% Upside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is held down primarily by weak financial performance (zero recent revenue, large losses, and significant cash burn with declining equity). Technical indicators provide some offset with improving short- to mid-term momentum, while valuation remains constrained by ongoing losses and no dividend yield data.

Positive Factors

Low leverage / no reported debt

Having no reported debt is a durable financial strength: it lowers bankruptcy risk and preserves strategic optionality for R&D funding, licensing or partnerships. Over a 2–6 month horizon this improves ability to absorb losses and pursue development milestones without immediate refinancing pressure.

Demonstrated ability to generate revenue and profits (2023)

Showing revenue and profitability in 2023 provides structural evidence the company can commercialize assets or monetize programs. That historical precedent increases long-term optionality for repeatable revenue streams, partnerships or licensing deals if clinical progress translates to marketable products.

Focused oncology small-molecule R&D addressing high unmet needs

A clear strategic focus on targeted oncology small molecules positions the firm in a structurally large, high-value market with persistent unmet need. Specialized R&D focus improves expertise accumulation and makes the company a more attractive partner or acquisition target if clinical assets advance.

Negative Factors

Zero recent revenue and large net losses

A return to zero revenue and large net losses is a durable negative: absent near-term revenue the firm lacks margin sustainability and operating leverage, increasing dependence on external capital. Over months this undermines ability to self-fund trials and reduces resilience against setbacks.

Sustained negative operating and free cash flow

Large, persistent cash burn is a structural risk: negative operating and free cash flow erode runway and force dilutive financing or urgent partnerships. Over a 2–6 month window this constrains strategic choices, raises refinancing risk and can delay or curtail clinical programs.

Declining equity and asset base reducing financial cushion

A materially shrinking equity and asset base weakens the company's capital cushion against losses and reduces flexibility to raise non-dilutive capital. This structural erosion increases vulnerability to adverse outcomes and limits ability to scale programs without external support.

Chordia Therapeutics Inc. Business Overview & Revenue Model

Company Description

Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.

How the Company Makes Money

Chordia Therapeutics Inc. primarily generates revenue through the development and commercialization of its proprietary drug candidates. The company earns income from licensing agreements, milestone payments, and royalties from partnerships with larger pharmaceutical companies. These collaborations often involve co-development or marketing arrangements that help Chordia Therapeutics bring its therapies to market. Additionally, the company may receive funding through grants, research collaborations, and potential government or non-governmental support aimed at fostering innovation in cancer treatment.

Chordia Therapeutics Inc. Financial Statement Overview

Summary

Income statement and cash flow are very weak: revenue fell back to a zero-revenue profile in 2024–2025 with large net losses and heavy operating/free-cash outflows. The balance sheet is helped by having no reported debt, but equity has declined materially, reflecting ongoing burn and weakening the capital base.

Income Statement

Operating performance has deteriorated sharply: after a profitable year in 2023 (revenue 2.5B and positive EBIT/Net Income), the company returned to a zero-revenue profile in 2024–2025 with very large losses (2025 Net Income about -1.79B). Margins are effectively nonexistent in the latest periods due to no revenue, and profitability is highly volatile—suggesting an early-stage/biotech-style earnings profile with limited near-term visibility. A key strength is that the business has demonstrated it can generate revenue and profits (2023), but the recent step-down back to heavy losses dominates the outlook.

Balance Sheet

The balance sheet shows no reported debt across periods, which reduces financial risk and improves flexibility. However, equity has declined materially (from ~4.50B in 2023 to ~2.44B in 2025), reflecting sustained losses and weakening the capital base; returns on equity are strongly negative in the most recent years (2025 ROE roughly -73%). Assets have also trended down versus the 2023–2024 levels, indicating cash burn and/or asset consumption. Overall: low leverage is a clear positive, but shrinking equity is a meaningful concern.

Cash Flow

Cash generation is weak and volatile: 2023 produced positive operating cash flow (~544M) and free cash flow (~543M), but 2024 and 2025 reverted to sizable cash outflows (operating cash flow about -1.94B in 2024 and -1.84B in 2025). Free cash flow is negative and worsening versus the prior profitable year, consistent with heavy investment/spend without offsetting revenue. A relative positive is that cash flow tracks net income closely (free cash flow to net income ~1x), but that mainly reflects that losses are translating into real cash burn.

Breakdown	Aug 2025	Aug 2024	Aug 2023	Aug 2022	Aug 2021
Income Statement
Total Revenue	0.00	0.00	2.50B	0.00	800.00M
Gross Profit	-1.43B	-4.09M	0.00	-3.15M	0.00
EBITDA	-1.79B	-1.82B	218.10M	-1.77B	-586.97M
Net Income	-1.79B	-1.83B	223.34M	-1.78B	-527.11M
Balance Sheet
Total Assets	2.68B	4.63B	4.91B	4.50B	2.27B
Cash, Cash Equivalents and Short-Term Investments	2.55B	4.33B	4.80B	4.25B	2.00B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	244.34M	471.07M	408.24M	221.41M	214.95M
Stockholders Equity	2.44B	4.16B	4.50B	4.28B	2.06B
Cash Flow
Free Cash Flow	-1.84B	-1.94B	543.01M	-1.72B	-546.92M
Operating Cash Flow	-1.84B	-1.94B	543.73M	-1.70B	-544.59M
Investing Cash Flow	-5.33M	-10.96M	345.00K	-14.70M	-2.36M
Financing Cash Flow	61.58M	1.48B	0.00	3.98B	1.53B

Chordia Therapeutics Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 108.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:190A, the sentiment is Negative. The current price of 108 is below the 20-day moving average (MA) of 126.95, below the 50-day MA of 123.38, and below the 200-day MA of 147.60, indicating a bearish trend. The MACD of 1.31 indicates Positive momentum. The RSI at 48.45 is Neutral, neither overbought nor oversold. The STOCH value of 36.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:190A.

Chordia Therapeutics Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4350	70 Outperform	¥15.66B	6.83	―	2.32%	6.60%	27.97%
4890	68 Neutral	¥9.83B	-11.77	―	―	-12.40%	43.42%
2796	60 Neutral	¥6.07B	11.29	―	2.65%	15.66%	56.93%
8095	58 Neutral	¥19.49B	8.55	―	3.73%	15.00%	-195.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
190A	47 Neutral	¥9.11B	-6.49	―	―	―	―

Chordia Therapeutics Inc. Corporate Events

Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort

Chordia Therapeutics Inc. has begun dosing the first patient in the Initial Expansion Cohort of its ongoing Phase 1/2 U.S. clinical trial of rogocekib, following a recommendation from the study’s Safety Review Committee. The transition to the expansion phase, after successful screening at multiple sites, marks a key step in evaluating the cancer drug’s potential across a broader patient group.

The company emphasized that patient safety remains its top priority as it advances the development program and plans to provide updates as the study progresses. This milestone underscores Chordia’s efforts to solidify its position in the oncology space by moving its lead candidate forward while continuing to build out a diversified pipeline of targeted cancer therapies.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen127.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.

Chordia Advances Rogocekib Leukemia Trial With FDA-Aligned Expansion Cohorts

Chordia Therapeutics Inc., a Japan-based oncology-focused biopharmaceutical developer, is advancing its pipeline of targeted cancer therapies led by rogocekib (CLK inhibitor CTX-712) in a Phase 1/2 U.S. trial. The company is also researching additional programs such as CTX-177, CTX-439, and GCN2 inhibitors to address a range of malignancies through precision approaches.

Chordia has decided to begin expansion cohorts in its ongoing Phase 1/2 study of rogocekib in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes in the United States, after an independent committee confirmed a dose level meeting predefined safety and efficacy criteria. The two-stage expansion, designed under U.S. FDA Project Optimus principles, will refine dosing, regimen, and tumor type to establish a recommended Phase 2 dose, with Phase 2 initiation targeted around mid‑2027 and dose-escalation data slated for presentation at an international conference in mid‑2026.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen111.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.

Chordia Regains Full Rights to CTX-177 After Ending Ono License Deal

Chordia Therapeutics has formally terminated its license agreement with Ono Pharmaceutical for CTX-177, a MALT1 inhibitor for lymphoid hematologic cancers, following Ono’s earlier strategic decision to halt development and return global rights. Under the agreement, Ono will transfer all clinical and non-clinical data to Chordia at no cost, end its Phase 1 trials in the U.S. and Japan, and allow Chordia to become the sole applicant on related combination-therapy patents, with the biotech expecting minimal impact on its FY2026 results.

With the termination complete, Chordia regains full control of CTX-177 and plans to leverage the inherited data to explore strategic options, including potential resumption of development or re-licensing to new partners. Management emphasizes that CTX-177 still shows strong scientific promise, and consolidating rights and data may strengthen Chordia’s negotiating position in business development while reinforcing its broader oncology pipeline strategy.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen115.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.

Chordia Therapeutics’ Major Shareholder Diluted Below 10% After Warrant Exercises

Chordia Therapeutics has announced a change in its major shareholder structure after the exercise of its 9th Series Stock Acquisition Rights and other stock acquisition rights increased the total number of voting rights outstanding. As a result, the stake of New Life Science I Investment Limited Partnership, a venture capital fund managed by Shinsei Capital Partners, was diluted from 10.51% to 9.99% of total voting rights, meaning it no longer qualifies as a major shareholder under the 10% threshold, although it remains the second-largest shareholder by rank. The company stated that this adjustment in ownership composition, driven by new share issuance rather than share sales, will have no impact on its management or business performance, suggesting limited immediate implications for corporate control or strategy.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen119.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.

Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink

Chordia Therapeutics reported non-consolidated results for the quarter ended 30 November 2025 showing no business revenue and a narrowed operating loss of ¥306 million, improving from a ¥624 million loss a year earlier, with quarterly net loss per share reduced to ¥4.24 from ¥9.07. Total assets declined to ¥2.48 billion and equity decreased slightly, but the company maintained a strong equity ratio of 92.1%, continued its no-dividend policy for the current and forecast fiscal year, and projected a full-year net loss of ¥1.96 billion, underscoring its ongoing investment phase and the likelihood of continued losses in the near term for shareholders.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen105.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.